Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
RENB 
Renovaro Biosciences Inc (RENB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: RENB (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 85.6% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 50.38M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.53 | 52 Weeks Range 0.27 - 2.10 | Updated Date 06/29/2025 |
52 Weeks Range 0.27 - 2.10 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.25 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -8.41% | Return on Equity (TTM) -53.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 55777031 | Price to Sales(TTM) - |
Enterprise Value 55777031 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -7.37 | Shares Outstanding 172119008 | Shares Floating 90925076 |
Shares Outstanding 172119008 | Shares Floating 90925076 | ||
Percent Insiders 47.27 | Percent Institutions 12.85 |
Upturn AI SWOT
Renovaro Biosciences Inc
Company Overview
History and Background
Renovaro Biosciences Inc., formerly known as Enochian Biosciences, is a biotechnology company focused on developing cell, gene, and immunotherapies for cancer and infectious diseases. Founded with a vision to innovate treatments for challenging health conditions, the company has undergone transformations in its focus and leadership. The company has focused on developing therapies using its proprietary HES platform.
Core Business Areas
- Immunotherapy Development: Focuses on developing immunotherapies for various cancer types.
- Cell Therapy Development: Developing cell-based therapies for treating diseases.
- Gene Therapy Development: Researching and developing gene therapies for cancer.
Leadership and Structure
The leadership team consists of individuals with experience in biotechnology and pharmaceuticals. Organizational structure includes research and development, clinical operations, and business development divisions.
Top Products and Market Share
Key Offerings
- REN-001: A cell-based immunotherapy currently in preclinical development for solid tumors. Market share is not yet applicable as it is pre-revenue and not yet commercialized. Competitors include companies developing similar cell therapies such as Allogene Therapeutics (ALLO), Fate Therapeutics (FATE), and CRISPR Therapeutics (CRSP).
- REN-002: Gene therapy research program addressing solid tumors. Market share is not yet applicable as it is pre-revenue and not yet commercialized. Competitors include companies developing similar gene therapies such as bluebird bio (BLUE), Novartis (NVS), and Roche (RHHBY).
Market Dynamics
Industry Overview
The biotechnology industry is rapidly evolving, with significant advancements in immunotherapy, cell therapy, and gene therapy. The market is highly competitive, with numerous companies vying for market share.
Positioning
Renovaro Biosciences Inc. is positioned as an early-stage biotechnology company focused on innovative therapies. The competitive advantage lies in the proprietary HES platform, which may provide unique capabilities in developing effective therapies.
Total Addressable Market (TAM)
The total addressable market for cancer therapies is estimated to be in the hundreds of billions of dollars annually. Renovaro Biosciences Inc. is positioned to capture a portion of this market through its innovative therapy pipeline, but its early stage means its current TAM capture is minimal. However, its TAM potential is large.
Upturn SWOT Analysis
Strengths
- Proprietary HES platform
- Focus on innovative therapies
- Experienced leadership team
Weaknesses
- Early-stage development
- Limited financial resources
- High reliance on clinical trial success
- Small market capitalization
Opportunities
- Partnerships with larger pharmaceutical companies
- Successful clinical trial results
- Expansion into new therapeutic areas
- Increased investment in immunotherapy research
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger companies
- Patent disputes
Competitors and Market Share
Key Competitors
- ALLO
- FATE
- CRSP
- BLUE
- NVS
- RHHBY
Competitive Landscape
Renovaro Biosciences Inc. faces intense competition from larger, more established biotechnology and pharmaceutical companies. The company's success depends on differentiating its therapies and achieving favorable clinical trial results.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company's early stage and lack of commercialized products.
Future Projections: Future growth projections are highly dependent on the success of clinical trials and securing partnerships. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing REN-001 and REN-002 through preclinical and clinical development, as well as pursuing strategic partnerships.
Summary
Renovaro Biosciences Inc. is an early-stage biotechnology company with a focus on innovative cancer therapies. The company's proprietary HES platform represents a strength, but limited financial resources and the inherent risks of clinical development pose challenges. Future success depends on positive clinical trial outcomes and strategic partnerships. Caution is warranted when considering investment in Renovaro Biosciences Inc.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Press Releases
- Third-party financial data providers
Disclaimers:
The information provided is for informational purposes only and should not be considered as financial advice. Investment decisions should be made based on independent research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Renovaro Biosciences Inc
Exchange NASDAQ | Headquaters Los Angeles, CA, United States | ||
IPO Launch date 2015-02-02 | CEO & Director Mr. David H. Weinstein | ||
Sector Healthcare | Industry Biotechnology | Full time employees 25 | Website https://renovarogroup.com |
Full time employees 25 | Website https://renovarogroup.com | ||
Renovaro Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company has a strategic collaboration with Nebul to advance the early detection of cancer and other diseases. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.